Australia, March 21 -- Annexon Inc., owns the trademark (2510924) for 'ANNEXON BIOSCIENCES' till Nov. 22, 2034.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barre syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG).], 42 [Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.] and 44 [Providing medical information; providing medical information related to pharmaceuticals.]
Type of Mark: Word
Date of Acceptance: Jan. 7
Registration Advertised: March 20
For further details contact Joshua S. Jarvis, Esq. Foley Hoag LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2510924.
Disclaimer: Curated by HT Syndication.
